Pyxis Oncology (PYXS) News Today

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been assigned an average rating of "Buy" from the seven ratings firms that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year target pr

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have earned an average recommendation of "Buy" from the seven brokerages that are covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year price target

Vestal Point Capital LP bought a new position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 440,000 shares of the company's stock, valued

Decheng Capital LLC acquired a new stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 326,810 shares of the company's stock, valued at approximately $588,000. Pyxis O

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have received an average rating of "Buy" from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year pric

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Stock analysts at William Blair cut their Q2 2024 earnings per share estimates for Pyxis Oncology in a report released on Tuesday, May 14th. William Blair analyst A. Hsieh now forecasts that the company will post earnings of ($0.34) per share for

HC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Thursday.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.19. The firm had revenue of $16.15 million during the quarter, compared to analysts' expectations of $4.25 million.

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) saw a significant decrease in short interest in April. As of April 30th, there was short interest totalling 1,850,000 shares, a decrease of 16.3% from the April 15th total of 2,210,000 shares. Approximately 4.0% of the shares of the stock are sold short. Based on an average daily volume of 749,400 shares, the short-interest ratio is presently 2.5 days.

abrdn plc acquired a new stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 708,303 shares of the company's stock, valued at approximately $1,275,000. abrdn plc owned approximately 1.60%

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) was the target of a large drop in short interest in April. As of April 15th, there was short interest totalling 2,210,000 shares, a drop of 18.1% from the March 31st total of 2,700,000 shares. Approximately 4.8% of the company's stock are short sold. Based on an average trading volume of 909,000 shares, the days-to-cover ratio is currently 2.4 days.

HC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Wednesday.

Royal Bank of Canada reaffirmed an "outperform" rating and set a $7.00 target price on shares of Pyxis Oncology in a report on Friday.

HC Wainwright increased their price target on shares of Pyxis Oncology from $4.00 to $7.00 and gave the stock a "buy" rating in a research note on Friday.

Pyxis Oncology (NASDAQ:PYXS) will be releasing earnings on Friday, March 22, Yahoo Finance reports.

Decheng Capital Management III Cayman LLC purchased a new position in Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 326,810 shares of